The present disclosure relates generally to the use of sphingolipid-metabolizing proteins to mitigate or minimize tissue damage resulting from injury or from disease, for example, pulmonary arterial hypertension (PAH) when the sphingolipid-metabolizing protein is delivered via expression from an Anc80 vector.

Provided are methods and compositions which are useful for separating, isolating, detecting, and quantifying compounds of interest which have been modified chemically, enzymatically or catalytically from other compounds which have not been so modified. The modifications may take the form of functional groups which are gained, lost or retained by the compounds of interest.

The present invention provides a sphingosine kinase 1, a fusion protein comprising the same, and a use thereof. The sphingosine kinase 1 and the fusion protein comprising the same have significant effects in lowering blood sugar and body weight, and are useful for the preparations of protein drugs for controlling metabolic diseases such as obesity and diabetes. It also provides a protein drug, which is a fusion protein containing a sphingosine kinase 1 or an amino acid sequence having the activity thereof. The fusion protein comprises a sphingosine kinase 1 (SPHK1) or an amino acid sequence having the activity thereof, a FC sequence and a linker sequence. The protein drug can significantly decrease blood sugar, blood fat and body weight, and improve fat metabolism.

Provided are methods and compositions which are useful for separating, isolating, detecting, and quantifying compounds of interest which have been modified chemically, enzymatically or catalytically from other compounds which have not been so modified. The modifications may take the form of functional groups which are gained, lost or retained by the compounds of interest.

The present invention relates to an inhibitor of sphingolipids for use in the treatment or prevention of an aging related-disease and/or aging.

A method for producing an objective substance such as sphingoid bases and sphingolipids using yeast is provided. An objective substance is produced by cultivating yeast having an ability to produce the objective substance in a culture medium containing an additive that is able to associate with, bind to, solubilize, and/or capture the objective substance, and collecting the objective substance from cells of the yeast and/or the culture medium.

A method for producing an objective substance such as phytosphingosine and sphinganine using yeast is provided. An objective substance is produced by cultivating yeast having an ability to produce the objective substance and modified so that the expression and/or activities of proteins encoded by LCB4 and CKA2 genes are reduced in a culture medium, and collecting the objective substance from cells of the yeast and/or the culture medium.

The present disclosure pertains to the use of an Anc80 viral vector that encodes a sphingolipid-metabolizing protein such as acid ceramidase to achieve expression of the sphingolipid-metabolizing protein in a mammalian cell or group of cells. Expression of the protein from the Anc80 vector reduces high levels of ceramide in the cell that lead to cell death or senescence.

The present disclosure pertains to the use of a modified RNA (modRNA) that encodes a sphingolipid-metabolizing protein such as acid ceramidase to achieve expression of the sphingolipid-metabolizing protein in a mammalian cell or group of cells. Expression of the protein from the (modRNA) reduces high levels of ceramide in the cell that lead to cell death or senescence.

The present disclosure pertains to the use of a modified RNA (modRNA) that encodes a sphingolipid-metabolizing protein such as acid ceramidase to achieve expression of the sphingolipid-metabolizing protein in a mammalian cell or group of cells. Expression of the protein from the (modRNA) reduces high levels of ceramide in the cell that lead to cell death or senescence.